Skip to Main Content

Top of the morning to you, and a fine one, it is. A sunny sky and a cool breeze are enveloping the cozy Pharmalot campus, where the usual routine was briefly altered when the short person required extra help reaching the local schoolhouse. Now, though, the rhythm has returned as we forage for items of interest. Speaking of which, here are some tidbits to help you along during what is likely to be a busy day, yes? So grab your cup of stimulation and dig in. Hope all goes well and do keep in touch. We enjoy hearing and reading secrets …

Shire (SHPG) filed an antitrust lawsuit accusing Allergan (AGN) of using contracts with Medicare Part D plans to block access to its Xiidra eye drops, which compete with Allergan’s Restasis drops. “We do not see how Allergan‘s discounting and rebating is different from the normal course of action in the pharmaceutical industry,” Wells Fargo analyst David Maris writes. “These allegations are very common,” Herbert Hovenkamp, an antitrust expert at the University of Pennsylvania, tells The Wall Street Journal. “They are not easy to prove.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.